Navigation Links
Top 100 Drug Sales Data Released - Plavix Leads the Way
Date:7/18/2012

NEW YORK, July 18, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2012 U.S. prescription sales data for the top 100 drugs.

Blood-thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers.

Top Five Drugs by Sales, Q1 2012 Drug Name

Sales ($000)

% Change (previous quarter)Plavix

1,620,790

2.85%Nexium

1,395,981

-3.08%Abilify

1,340,200

4.46%Singulair

1,238,134

8.67%Seroquel

1,161,141

3.29%Bristol-Myers Squibb's Plavix leads the way with over $1.6 billion in sales in the first quarter of 2012. However, the recent launch of clopidogrel (the generic version of Plavix) may alter these figures in upcoming quarters. Proton-pump inhibitor Nexium sees a small decline, while sales for Abilify and Singulair both exceeded $1 billion. The generic version of Singulair (montelukast) is slated for market entry in Q3 2012.

"The most recent sales data from the first quarter of 2012 highlights the continued stronghold of several branded medications," said Philip Thornton, CEO of Drugs.com. "However, with generic versions of Plavix and Lipitor now available and with a number of established brands moving to first-time generic status in the coming years, lower-cost medications will enable patients to have greater access to lifesaving treatments and save billions in healthcare dollars."

Top Sales Gains and Losses in Q1 2012Atorvastatin and its branded version Lipitor claim both the top gain and loss, respectively, in Q1 2012.

Q1 2012 Top Five Sales GainsDrug Name

Gain ($000)

% Changeatorvastatin

$447,316

+88.56%Synagis

$109,826

+38.30%Singulair

$98,833

+8.67%Remicade

$82,088

+10.04%Cymbalta

$72,540

+7.58%Atorvastatin makes the biggest gain, bringing total sales in Q1 2012 to $952 million. As a comparison, Lipitor sales reached $1.9 billion in each of the first three quarters of 2011.

Synagis, MedImmune's monoclonal antibody used for prevention of respiratory syncytial virus (RSV) in infants and young children, gains 38 percent.

Q1 2012 Top Five Sales LossesDrug Name

Loss ($000)

% ChangeLipitor

-760,948

-47.51%Lexapro

-227,560

-31.67%Zyprexa

-184,540

-49.69%Epogen

-159,223

-24.52%Incivek

-75,404

-16.88%Pfizer's cholesterol-lowering statin Lipitor lost patent protection in 2011 and sales of the brand dropped to 14th position.

Eli Lilly's Zyprexa drops 43 places to 84th and closes the quarter with $194 million. Sales of Forest Laboratories' popular antidepressant Lexapro also declined due to the availability of its generic counterpart, escitalopram.

Detailed data on the top 100 drugs can be accessed at: http://www.drugs.com/stats/top100/sales

About Drugs.comDrugs.com is the leading online drug information resource with over seven million unique visitors per month (ComScore, June 2012). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:

Drugs.com Press Officer
press@drugs.com
(718) 395 2473

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
4. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
5. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
6. SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. Allied Healthcare Products Reports Loss on Sales Decline
9. Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
10. Millennium Surgical Corp. Announces Sales Figures, Growth
11. Cephasonics Inks Distribution Deal With Tritech To Extend Worldwide Sales Reach Into Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):